DSM Pharmaceutical Products, a leading provider of custom contract manufacturing services, announced today the following management appointments.

Mr. Leendert Staal, currently Business Group Director DSM Pharmaceutical Products, will be appointed President of DSM Nutritional Products, reporting to Stephan Tanda, member of the Managing Board of DSM.

Mr. Bob Hartmayer will succeed Mr. Staal as Business Group Director, President & CEO of DSM Pharmaceutical Products, reporting to Jan Zuidam, member of the Managing Board of DSM. Mr. Hartmayer currently holds the position of Business Group Director DSM Elastomers.

As the pharmaceutical business group is now moving into a significant period of growth, involving both autonomous and non-autonomous opportunities, the following management appointments will take effect on October 1, 2007;

Mr. Luca Mantovani, currently Vice President Citric Acid, DSM Nutritional Products, will be appointed Business Unit Director, President DSM Pharma Chemicals reporting to Mr. Hartmayer. 

Mr. Terry Novak, currently Chief Marketing Officer DSM Pharmaceuticals & Biologics, will be appointed Business Unit Director, President DSM Pharmaceuticals Inc. reporting to Mr. Hartmayer.

Ms. Karen King, currently Sr. VP Strategic Business Development, will be appointed Business Unit Director, President DSM Biologics reporting to Mr. Hartmayer.

Mr. Hans Engels, currently Chief Operating Officer DSM Pharmaceuticals & Biologics will be appointed Chief Operating Officer, DSM Pharmaceutical Products Business Group reporting to Mr. Hartmayer.

Mr. Stephen Lijoi, currently VP Operations Greenville, will be appointed Vice President and Site Director for DSM Pharmaceuticals Greenville, NC site reporting to Mr. Novak.

About DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing services to the pharmaceutical and biopharmaceutical industries. DSM Pharmaceutical Products provides contract manufacturing services including: advanced intermediates, active ingredients (API's), amino acids and derivatives, mammalian cell culture production (fed-batch and perfusion) of monoclonal antibodies, proteins, vaccines, finished dose manufacturing of solid dose, scheduled drugs, liquids, aseptic liquid and lyophilized products.

From clinical to commercial services, DSM focuses the right resources on providing the highest level of service and quality while applying innovative solutions to satisfy customers’ unique manufacturing needs.